logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Presentation at Conference and Notice of Results

RNS Number : 5016I
Silence Therapeutics PLC
02 April 2020
 

 

Silence Therapeutics to Deliver Virtual Presentation at the Annual Needham Healthcare Conference and Announces Notice of Full Year Results

 

2 April 2020

 

 

LONDONSilence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Dr. Rob Quinn, Chief Financial Officer, will conduct a virtual presentation at the 19th Annual Needham Healthcare Conference on Tuesday, 14 April 2020, at 14:20 BST (9:20 a.m. ET).

 

A live webcast of the Company's virtual presentation can be accessed by visiting 'Results, reports & presentations' in the Investors Section of the Company's website at www.silence-therapeutics.com. An archived replay of the webcast will be available for 60 days on the Company's website after the conference.

 

Silence also confirms that it will announce final results for the full year ended 31 December 2019 on 14 April. Iain Ross, Executive Chairman and Dr Rob Quinn, Chief Financial Officer will host a webcast and live conference call for analysts and investors at 13:00 BST (8:00 a.m. ET) on the day of the results. Details of the webcast and conference call will be provided prior to the event.

 

 

 

 

 

For more information, please contact:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke

Peter Vozzo

[email protected]

 Tel: +1 (443) 213-0505

 

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using its enabling delivery systems, it has achieved an additional level of specificity by delivering its therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. Silence Therapeutics remains focused and is determined to be responsive to creating shareholder value as well as the appropriate growth and development of its business. Silence Therapeutics continues to assess a number of options in addition to its organic plan which it believes would be additive to the Company's future growth prospects and shareholder value, which may include equity fundraisings as well as other strategic licensing and collaboration opportunities. For more information, please visit: https://www.silence-therapeutics.com/

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCUPUPWCUPUPUG

Quick facts: Silence Therapeutics PLC

Price: 464

Market: AIM
Market Cap: £384.31 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics feels move to NASDAQ will give its tech the...

Silence Therapeutics PLC's (LON:SLN) chairman Iain Ross and CFO Rob Quinn speak to Proactive London's Andrew Scott after announcing its intention to list on the American growth market, Nasdaq. Ross says in the US, RNAi is very hot at the moment and if you look at their competitor companies...

on 22/5/20